Identification

Name
Sulindac
Accession Number
DB00605  (APRD01243)
Type
Small Molecule
Groups
Approved
Description

Sulindac is a nonsteroidal anti-inflammatory agent (NSAIA) of the arylalkanoic acid class that is marketed in the U.S. by Merck as Clinoril. Like other NSAIAs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted in vivo to an active sulfide compound by liver enzymes. The sulfide metabolite then undergoes enterohepatic circulation; it is excreted in the bile and then reabsorbed from the intestine. This is thought to help maintain constant blood levels with reduced gastrointestinal side effects. Some studies have shown sulindac to be relatively less irritating to the stomach than other NSAIA's except for drugs of the cyclooxygenase-2 (COX-2) inhibitor class. The exact mechanism of its NSAIA properties is unknown, but it is thought to act on enzymes COX-1 and COX-2, inhibiting prostaglandin synthesis.

Structure
Thumb
Synonyms
  • (Z)-5-Fluoro-2-methyl-1-((P-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
  • cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
  • cis-5-Fluoro-2-methyl-1-((P-methylsulfinyl)benzylidene)indene-3-acetic acid
  • Sulindac
  • Sulindaco
  • Sulindacum
Product Ingredients
IngredientUNIICASInChI Key
Sulindac sodiumNJV14I2XPC63804-15-9YMXUJDLCLXHYBO-WPTDRQDKSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clinoril Tab 150mgTablet150 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1979-12-311998-08-14Canada
Clinoril Tab 200mgTablet200 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1979-12-311998-08-14Canada
Nu-sulindac Tab 150mgTablet150 mgOralNu Pharm Inc1994-12-312012-09-04Canada
Nu-sulindac Tab 200mgTablet200 mgOralNu Pharm Inc1994-12-312012-09-04Canada
Penta-sulindacTablet150 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-sulindacTablet200 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Sulindac-150 Tab 150mgTablet150 mgOralPro Doc Limitee1989-12-312009-07-23Canada
Sulindac-200 Tab 200mgTablet200 mgOralPro Doc Limitee1989-12-312009-07-23Canada
Teva-sulindacTablet150 mgOralTeva1988-12-31Not applicableCanada
Teva-sulindacTablet200 mgOralTeva1988-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sulin Tab 150mgTablet150 mgOralApotex Corporation1988-12-31Not applicableCanada
Apo-sulin Tab 200mgTablet200 mgOralApotex Corporation1988-12-31Not applicableCanada
SulindacTablet200 mg/1OralEpic Pharma, LLC2015-07-28Not applicableUs
SulindacTablet200 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
SulindacTablet200 mg/1OralCarilion Materials Management1990-04-03Not applicableUs
SulindacTablet150 mg/1OralActavis Pharma Company1990-04-03Not applicableUs
SulindacTablet150 mg/1OralGolden State Medical Supply2010-01-25Not applicableUs
SulindacTablet150 mg/1OralPura Cap Pharmaceutical Llc.2016-11-14Not applicableUs
SulindacTablet150 mg/1OralMylan Pharmaceuticals1993-06-22Not applicableUs
SulindacTablet150 mg/1Oralbryant ranch prepack1990-04-032017-06-20Us00591 5661 01 nlmimage10 520ea935
International/Other Brands
Clinoril (Merck)
Categories
UNII
184SNS8VUH
CAS number
38194-50-2
Weight
Average: 356.411
Monoisotopic: 356.088243305
Chemical Formula
C20H17FO3S
InChI Key
MLKXDPUZXIRXEP-MFOYZWKCSA-N
InChI
InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
IUPAC Name
2-[(1Z)-5-fluoro-1-[(4-methanesulfinylphenyl)methylidene]-2-methyl-1H-inden-3-yl]acetic acid
SMILES
CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O

Pharmacology

Indication

For acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis.

Structured Indications
Pharmacodynamics

Sulindac is a non-steroidal anti-inflammatory indene derivative, also possessing analgesic and antipyretic activities.

Mechanism of action

Sulindac's exact mechanism of action is unknown. Its antiinflammatory effects are believed to be due to inhibition of both COX-1 and COX-2 which leads to the inhibition of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UProstaglandin G/H synthase 1
inhibitor
Human
UAldose reductase
inhibitor
Human
UMitogen-activated protein kinase 3
inhibitor
Human
UPeroxisome proliferator-activated receptor delta
negative modulator
Human
UProstaglandin D2 receptor 2
antagonist
Human
UAldo-keto reductase family 1 member B10
inhibitor
Human
Absorption

Approximately 90% absorbed in humans following oral administration.

Volume of distribution
Not Available
Protein binding

At 1 mcg/ml concentrations, approximately 93% sulindac and 98% of its sulfide metabolite are bound to human serum albumin.

Metabolism

Undergoes two major biotransformations: reversible reduction to the sulfide metabolite, and irreversible oxidation to the sulfone metabolite. Sulindac and its sulfide and sulfone metabolites undergo extensive enterohepatic circulation. Available evidence indicates that the biological activity resides with the sulfide metabolite. Side chain hydroxylation and hydration of the double bond also occur.

Route of elimination

Sulindac is excreted in rat milk; concentrations in milk were 10 to 20% of those levels in plasma. It is not known if sulindac is excreted in human milk. Approximately 50% of the administered dose of sulindac is excreted in the urine with the conjugated sulfone metabolite accounting for the major portion. Hepatic metabolism is an important elimination pathway.

Half life

The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.

Clearance
  • Renal cl=68.12 +/- 27.56 mL/min [NORMAL (19-41 yrs)]
Toxicity

Acute oral toxicity (LD50) in rats is 264 mg/kg. Cases of overdose have been reported and rarely, deaths have occurred. The following signs and symptoms may be observed following overdose: stupor, coma, diminished urine output and hypotension.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Sulindac Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Sulindac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Sulindac is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Sulindac is combined with 5-androstenedione.Experimental, Illicit
AbciximabSulindac may increase the anticoagulant activities of Abciximab.Approved
AcebutololSulindac may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Sulindac is combined with Aceclofenac.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Sulindac is combined with Acemetacin.Approved
AcenocoumarolSulindac may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Sulindac.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Sulindac.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinSulindac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Sulindac.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Sulindac is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Sulindac is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Alendronic acid.Approved
AliskirenSulindac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Alminoprofen.Experimental
AlprenololSulindac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Sulindac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Sulindac is combined with Amcinonide.Approved
AmikacinSulindac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideSulindac may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinSulindac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodSulindac may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Sulindac is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Sulindac is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Sulindac is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Sulindac is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Sulindac is combined with Anisodamine.Investigational
annamycinSulindac may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Sulindac is combined with Antipyrine.Approved
Antithrombin III humanSulindac may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanSulindac may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Sulindac is combined with Apocynin.Investigational
ApramycinSulindac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Sulindac is combined with Apremilast.Approved, Investigational
ArbekacinSulindac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinSulindac may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanSulindac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololSulindac may decrease the antihypertensive activities of Arotinolol.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Sulindac is combined with Atamestane.Investigational
AtenololSulindac may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Sulindac is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sulindac.Approved
BalsalazideSulindac may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminSulindac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Sulindac is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololSulindac may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinSulindac may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Sulindac.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Sulindac is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Sulindac.Approved
BenorilateThe risk or severity of adverse effects can be increased when Sulindac is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Sulindac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Betamethasone.Approved, Vet Approved
BetaxololSulindac may decrease the antihypertensive activities of Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Sulindac.Approved, Investigational
BevantololSulindac may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Sulindac is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Sulindac.Approved, Investigational
BisoprololSulindac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinSulindac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololSulindac may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Sulindac is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Sulindac is combined with Bucillamine.Investigational
BucindololSulindac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Sulindac is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Sulindac is combined with Bufexamac.Experimental
BufuralolSulindac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Bumadizone.Experimental
BumetanideSulindac may decrease the diuretic activities of Bumetanide.Approved
BupranololSulindac may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sulindac.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Sulindac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Sulindac.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Sulindac.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Sulindac is combined with Carbaspirin calcium.Experimental
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Sulindac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololSulindac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSulindac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Sulindac is combined with Castanospermine.Experimental
CeliprololSulindac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinSulindac may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Sulindac is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulindac.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Sulindac.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Sulindac is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Sulindac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sulindac.Approved
CinoxacinSulindac may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
Citric AcidSulindac may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Sulindac is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Sulindac is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Sulindac is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Sulindac is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Sulindac is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Sulindac.Vet Approved
CloranololSulindac may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Sulindac is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Sulindac is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Sulindac is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Sulindac is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Sulindac.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Sulindac.Approved, Investigational
CyclosporineSulindac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Sulindac.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when Sulindac is combined with D-Limonene.Investigational
Dabigatran etexilateSulindac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinSulindac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSulindac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanSulindac may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinSulindac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Sulindac is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Sulindac.Experimental
DesirudinSulindac may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Sulindac.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Sulindac is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Sulindac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Sulindac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Sulindac is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulindac.Approved
DextranSulindac may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Sulindac may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Sulindac may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Sulindac may increase the anticoagulant activities of Dextran 75.Approved
DibekacinSulindac may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Sulindac.Approved, Vet Approved
DicoumarolSulindac may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Sulindac is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Sulindac is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Sulindac is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Sulindac is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Sulindac.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Sulindac.Approved
DihydrostreptomycinSulindac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
Dimethyl sulfoxideThe metabolism of Sulindac can be decreased when combined with Dimethyl sulfoxide.Approved, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Sulindac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Sulindac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Sulindac.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sulindac.Approved, Investigational
DoxorubicinSulindac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneSulindac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Sulindac is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Sulindac is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Sulindac is combined with E-6201.Investigational
Edetic AcidSulindac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSulindac may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Sulindac.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sulindac.Approved
EnoxacinSulindac may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinSulindac may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Sulindac.Experimental
EpanololSulindac may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Sulindac is combined with Epirizole.Approved
EpirubicinSulindac may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneSulindac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Sulindac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sulindac.Approved
EquileninThe risk or severity of adverse effects can be increased when Sulindac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Sulindac is combined with Equilin.Approved
EsmololSulindac may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Sulindac is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Sulindac is combined with Estrone sulfate.Approved
Etacrynic acidSulindac may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Sulindac.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Sulindac is combined with Ethenzamide.Experimental
Ethyl biscoumacetateSulindac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Sulindac is combined with Etofenamate.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Sulindac is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Sulindac is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Sulindac is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Sulindac is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Sulindac.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Sulindac.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Feprazone.Experimental
Ferulic acidSulindac may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Sulindac.Approved
FleroxacinSulindac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Sulindac.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Sulindac is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Fludrocortisone.Approved
FluindioneSulindac may increase the anticoagulant activities of Fluindione.Investigational
FlumequineSulindac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Sulindac is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Sulindac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Sulindac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Sulindac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Sulindac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Sulindac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Sulindac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Sulindac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Flurbiprofen.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Sulindac.Approved, Nutraceutical, Vet Approved
FondaparinuxSulindac may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumSulindac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Sulindac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Sulindac is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sulindac.Approved
FramycetinSulindac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideSulindac may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateSulindac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinSulindac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSulindac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Sulindac.Approved, Withdrawn
GemifloxacinSulindac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinSulindac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinSulindac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ASulindac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GitoformateGitoformate may decrease the cardiotoxic activities of Sulindac.Experimental
GPX-150Sulindac may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinSulindac may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Sulindac is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Sulindac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Sulindac is combined with HE3286.Investigational
HeparinSulindac may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Sulindac is combined with Higenamine.Investigational
HydralazineSulindac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sulindac.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Sulindac.Approved
Hygromycin BSulindac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Sulindac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Sulindac is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Sulindac is combined with Icatibant.Approved
IdarubicinSulindac may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxSulindac may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Sulindac.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Sulindac.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Sulindac is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Sulindac.Approved
IndenololSulindac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Sulindac is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Sulindac.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Indoprofen.Withdrawn
INNO-206Sulindac may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sulindac.Approved, Investigational
IsepamicinSulindac may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Sulindac is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Sulindac is combined with Istaroxime.Investigational
KanamycinSulindac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Sulindac.Approved
LabetalolSulindac may decrease the antihypertensive activities of Labetalol.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Sulindac.Experimental
LandiololSulindac may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Sulindac.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Sulindac.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Sulindac is combined with Leflunomide.Approved, Investigational
LepirudinSulindac may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanSulindac may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololSulindac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSulindac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Sulindac.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Sulindac.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Sulindac is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Sulindac.Approved
LonazolacThe risk or severity of adverse effects can be increased when Sulindac is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Sulindac is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Sulindac.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Sulindac.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Sulindac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Sulindac is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Sulindac.Approved
ME-609The risk or severity of adverse effects can be increased when Sulindac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Mefenamic acid.Approved
MelagatranSulindac may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Sulindac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Sulindac is combined with Meloxicam.Approved, Vet Approved
MepindololSulindac may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineSulindac may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Sulindac is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Sulindac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sulindac.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Sulindac is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Sulindac.Experimental
MetipranololSulindac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Sulindac.Approved
MetoprololSulindac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideSulindac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinSulindac may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Sulindac.Approved
MizoribineThe risk or severity of adverse effects can be increased when Sulindac is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Sulindac.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Mofebutazone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Sulindac.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Sulindac is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Mycophenolic acid.Approved
NadololSulindac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinSulindac may increase the anticoagulant activities of Nadroparin.Approved
NafamostatSulindac may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Sulindac is combined with Naftifine.Approved
Nalidixic AcidSulindac may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Sulindac is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Sulindac is combined with NCX 1022.Investigational
NeamineSulindac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinSulindac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinSulindac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Sulindac is combined with Nepafenac.Approved
NetilmicinSulindac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Sulindac is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Sulindac is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Sulindac is combined with Nitroaspirin.Investigational
NorfloxacinSulindac may increase the neuroexcitatory activities of Norfloxacin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Sulindac.Experimental
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Sulindac is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sulindac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Sulindac is combined with Olopatadine.Approved
OlsalazineSulindac may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Sulindac is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Sulindac.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Sulindac is combined with Orgotein.Vet Approved
OtamixabanSulindac may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Sulindac.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Sulindac is combined with Oxaprozin.Approved
Oxolinic acidSulindac may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololSulindac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sulindac.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Sulindac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Paramethasone.Approved
ParomomycinSulindac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Sulindac is combined with Parthenolide.Investigational
PazufloxacinSulindac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSulindac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololSulindac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateSulindac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Sulindac.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Sulindac.Experimental
PhenindioneSulindac may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonSulindac may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sulindac.Approved, Investigational
PindololSulindac may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidSulindac may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinSulindac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideSulindac may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Pirfenidone.Investigational
Piromidic acidSulindac may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Sulindac.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Pirprofen.Experimental
PlazomicinSulindac may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinSulindac may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Sulindac.Approved
PractololSulindac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Sulindac.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Pranoprofen.Experimental
PrasteroneThe risk or severity of adverse effects can be increased when Sulindac is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Sulindac is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Sulindac is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Sulindac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Sulindac is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Sulindac can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Sulindac is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Sulindac is combined with Propacetamol.Approved
PropranololSulindac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Proquazone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Sulindac.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Sulindac.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Sulindac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Sulindac.Vet Approved
Protein CSulindac may increase the anticoagulant activities of Protein C.Approved
Protein S humanSulindac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSulindac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinSulindac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Sulindac is combined with PTC299.Investigational
PuromycinSulindac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Sulindac.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Sulindac.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Sulindac.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sulindac.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Sulindac is combined with Resveratrol.Experimental, Investigational
ReviparinSulindac may increase the anticoagulant activities of Reviparin.Approved
RibostamycinSulindac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Sulindac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Sulindac is combined with Risedronate.Approved, Investigational
RivaroxabanSulindac may increase the anticoagulant activities of Rivaroxaban.Approved
RosoxacinSulindac may increase the neuroexcitatory activities of Rosoxacin.Approved
RufloxacinSulindac may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinSulindac may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Sulindac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Sulindac is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Sulindac is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Sulindac.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Sulindac.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Sulindac is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Sulindac is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Sulindac is combined with Serrapeptase.Investigational
SisomicinSulindac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinSulindac may increase the neuroexcitatory activities of Sitafloxacin.Experimental
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Sulindac.Approved
SotalolSulindac may decrease the antihypertensive activities of Sotalol.Approved
SP1049CSulindac may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinSulindac may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinSulindac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Sulindac.Approved
SpironolactoneSulindac may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Sulindac is combined with SRT501.Investigational
StreptomycinSulindac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinSulindac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulindac is combined with Sulfasalazine.Approved
SulodexideSulindac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Sulindac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Suxibuzone.Experimental
TacrolimusSulindac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Sulindac.Approved
TalinololSulindac may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Sulindac.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Sulindac is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Sulindac.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Sulindac is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Sulindac is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sulindac.Approved, Investigational
TemafloxacinSulindac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Sulindac.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Sulindac is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Sulindac is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Sulindac.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Sulindac is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Sulindac is combined with Teriflunomide.Approved
TertatololSulindac may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Tiludronic acid.Approved, Vet Approved
TimololSulindac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Sulindac is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Sulindac is combined with Tixocortol.Approved
TobramycinSulindac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Sulindac is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Sulindac.Approved
TorasemideSulindac may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Sulindac.Approved
TranilastThe risk or severity of adverse effects can be increased when Sulindac is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Sulindac.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Sulindac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Sulindac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Sulindac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneSulindac may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Sulindac is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Sulindac.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Sulindac is combined with Triptolide.Investigational
TrovafloxacinSulindac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
TroxerutinSulindac may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Sulindac.Approved
ValrubicinSulindac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Sulindac.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Sulindac.Approved
WarfarinSulindac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSulindac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Sulindac is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Sulindac.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Sulindac is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinSulindac may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinSulindac may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Gary Piazza, Robert Reynolds, "Derivatives of sulindac, use thereof and preparation thereof." U.S. Patent US20070244122, issued October 18, 2007.

US20070244122
General References
Not Available
External Links
Human Metabolome Database
HMDB14743
KEGG Drug
D00120
KEGG Compound
C01531
PubChem Compound
1548887
PubChem Substance
46506570
ChemSpider
1265915
BindingDB
50012899
ChEBI
9352
ChEMBL
CHEMBL15770
Therapeutic Targets Database
DAP000569
PharmGKB
PA451565
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Sulindac
ATC Codes
M01AB02 — Sulindac
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
FDA label
Download (106 KB)
MSDS
Download (73.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionCancer, Breast1
2Active Not RecruitingTreatmentDesmoid Tumors1
2CompletedPreventionAdenomatous Polyposis Coli1
2CompletedPreventionMalignant Neoplasm of Colon / Precancerous Conditions / Rectal Carcinoma1
2CompletedPreventionPrecancerous Conditions1
2CompletedPreventionPrecancerous Conditions / Stage I Non-Small Cell Lung Cancer / Tobacco Use Disorders1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2RecruitingPreventionCancers / Hypertensive / Inflammatory Reaction / Pain1
2TerminatedPreventionColorectal Cancers1
2TerminatedTreatmentColorectal Adenocarcinoma / Colorectal Cancers / Liver Metastasis1
2Unknown StatusPreventionAdenomatous Polyposis Coli1
2WithdrawnDiagnosticFocus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms1
2WithdrawnTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3Active Not RecruitingTreatmentFamilial Adenomatous Polyposis (FAP)1
3CompletedPreventionPrecancerous Conditions1
Not AvailableActive Not RecruitingTreatmentNeoplasms, Benign / Oral Leukoplakia1
Not AvailableCompletedPreventionUnspecified Adult Solid Tumor, Protocol Specific1
Not AvailableTerminatedPreventionAberrant Crypt Foci1
Not AvailableTerminatedPreventionColorectal Cancers1

Pharmacoeconomics

Manufacturers
  • Merck research laboratories div merck co inc
  • Epic pharma llc
  • Heritage pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral150 mg/1
TabletOral200 mg/1
TabletOral150 mg
TabletOral200 mg
Prices
Unit descriptionCostUnit
Sulindac powder17.36USD g
Clinoril 200 mg tablet1.58USD tablet
Sulindac 200 mg tablet1.23USD tablet
Sulindac 150 mg tablet1.0USD tablet
Apo-Sulin 200 mg Tablet0.51USD tablet
Novo-Sundac 200 mg Tablet0.51USD tablet
Nu-Sulindac 200 mg Tablet0.51USD tablet
Apo-Sulin 150 mg Tablet0.4USD tablet
Novo-Sundac 150 mg Tablet0.4USD tablet
Nu-Sulindac 150 mg Tablet0.4USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)183 °CPhysProp
water solubility3000 mg/LMERCK INDEX (1996); pH 7
logP3.42SANGSTER (1993)
pKa4.7MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0251 mg/mLALOGPS
logP2.96ALOGPS
logP2.93ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)4.09ChemAxon
pKa (Strongest Basic)-6.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity99.56 m3·mol-1ChemAxon
Polarizability37.2 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9937
Blood Brain Barrier+0.8325
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.5904
P-glycoprotein inhibitor INon-inhibitor0.5847
P-glycoprotein inhibitor IINon-inhibitor0.9949
Renal organic cation transporterNon-inhibitor0.8753
CYP450 2C9 substrateNon-substrate0.7715
CYP450 2D6 substrateNon-substrate0.8961
CYP450 3A4 substrateNon-substrate0.5629
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5789
Ames testNon AMES toxic0.5451
CarcinogenicityNon-carcinogens0.6516
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0989 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9768
hERG inhibition (predictor II)Non-inhibitor0.8671
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0019000000-fec3a7dbf1ba6b64f03e
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0019000000-6a9b19701aa1af58166d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001l-0095000000-1aef30e1f36f3fcc9ea2
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001j-0090000000-4f30705a14fab7bb25e0
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0090000000-8bf873219e6e4353be1e
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-000y-0095000000-0a507959838acf3f73cb
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0059000000-3ad0cecc4eb73cce225e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0069000000-be643d55172bd2292511
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001j-1290000000-33b23a68145a3ef2000c

Taxonomy

Description
This compound belongs to the class of organic compounds known as indenes and isoindenes. These are compounds containing an indene moiety(which consists of a cyclopentadiene fused to a benzene ring), or a isoindene moiety (which consists of a cyclopentadiene fused to cyclohexadiene ring).
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Indenes and isoindenes
Sub Class
Not Available
Direct Parent
Indenes and isoindenes
Alternative Parents
Phenyl sulfoxides / Aryl fluorides / Sulfoxides / Sulfinyl compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Organofluorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Phenyl sulfoxide / Indene / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Sulfoxide / Sulfinyl compound / Carboxylic acid derivative / Carboxylic acid / Monocarboxylic acid or derivatives
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
organofluorine compound, monocarboxylic acid, sulfoxide (CHEBI:9352)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Giuliano F, Warner TD: Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol. 1999 Apr;126(8):1824-30. [PubMed:10372826]
  2. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999 Sep 1;59(17):4356-62. [PubMed:10485483]
  3. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000 Feb;21(2):139-46. [PubMed:10657949]
  4. Fosslien E: Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000 Oct;37(5):431-502. [PubMed:11078056]
  5. Taylor MT, Lawson KR, Ignatenko NA, Marek SE, Stringer DE, Skovan BA, Gerner EW: Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res. 2000 Dec 1;60(23):6607-10. [PubMed:11118042]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Giuliano F, Warner TD: Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol. 1999 Apr;126(8):1824-30. [PubMed:10372826]
  2. Lim JT, Piazza GA, Han EK, Delohery TM, Li H, Finn TS, Buttyan R, Yamamoto H, Sperl GJ, Brendel K, Gross PH, Pamukcu R, Weinstein IB: Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol. 1999 Oct 1;58(7):1097-107. [PubMed:10484067]
  3. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr, Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 1999 Dec 15;59(24):6178-84. [PubMed:10626810]
  4. Cheng ZJ, Tikkanen I, Vapaatalo H, Mervaala EM: Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene. J Physiol Pharmacol. 2002 Dec;53(4 Pt 1):597-613. [PubMed:12512695]
  5. Cheng ZJ, Finckenberg P, Louhelainen M, Merasto S, Tikkanen I, Vapaatalo H, Mervaala EM: Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27). Eur J Pharmacol. 2003 Feb 14;461(2-3):159-69. [PubMed:12586211]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Glyceraldehyde oxidoreductase activity
Specific Function
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies.
Gene Name
AKR1B1
Uniprot ID
P15121
Uniprot Name
Aldose reductase
Molecular Weight
35853.125 Da
References
  1. Sharma YR, Vajpayee RB, Bhatnagar R, Mohan M, Azad RV, Kumar M, Nath R: Topical sulindac therapy in diabetic senile cataracts: cataract-IV. Indian J Ophthalmol. 1989 Jul-Sep;37(3):127-33. [PubMed:2632448]
  2. Crabbe MJ, Freeman G, Halder AB, Bron AJ: The inhibition of bovine lens aldose reductase by Clinoril, its absorption into the human red cell and its effect on human red cell aldose reductase activity. Ophthalmic Res. 1985;17(2):85-9. [PubMed:3920599]
  3. Chaudhry PS, Cabrera J, Juliani HR, Varma SD: Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8. [PubMed:6409111]
  4. Jacobson M, Sharma YR, Cotlier E, Hollander JD: Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors. Invest Ophthalmol Vis Sci. 1983 Oct;24(10):1426-9. [PubMed:6413448]
  5. van der Sloot P, Mizisin A, Zochodne D: Sulindac in established experimental diabetes: a follow-up study. Can J Neurol Sci. 1995 Aug;22(3):198-201. [PubMed:8529171]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Phosphatase binding
Specific Function
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK ca...
Gene Name
MAPK3
Uniprot ID
P27361
Uniprot Name
Mitogen-activated protein kinase 3
Molecular Weight
43135.16 Da
References
  1. Rice PL, Goldberg RJ, Ray EC, Driggers LJ, Ahnen DJ: Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res. 2001 Feb 15;61(4):1541-7. [PubMed:11245463]
  2. Rice PL, Washington M, Schleman S, Beard KS, Driggers LJ, Ahnen DJ: Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res. 2003 Feb 1;63(3):616-20. [PubMed:12566304]
  3. Rice PL, Beard KS, Driggers LJ, Ahnen DJ: Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. Cancer Res. 2004 Nov 15;64(22):8148-51. [PubMed:15548677]
  4. Pangburn HA, Kraus H, Ahnen DJ, Rice PL: Sulindac metabolites inhibit epidermal growth factor receptor activation and expression. J Carcinog. 2005 Sep 2;4:16. [PubMed:16138927]
  5. Rice PL, Peters SL, Beard KS, Ahnen DJ: Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways. Mol Cancer Ther. 2006 Mar;5(3):746-54. [PubMed:16546990]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Negative modulator
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-lin...
Gene Name
PPARD
Uniprot ID
Q03181
Uniprot Name
Peroxisome proliferator-activated receptor delta
Molecular Weight
49902.99 Da
References
  1. He TC, Chan TA, Vogelstein B, Kinzler KW: PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999 Oct 29;99(3):335-45. [PubMed:10555149]
  2. Babbar N, Ignatenko NA, Casero RA Jr, Gerner EW: Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem. 2003 Nov 28;278(48):47762-75. Epub 2003 Sep 23. [PubMed:14506281]
  3. Jarvis MC, Gray TJ, Palmer CN: Both PPARgamma and PPARdelta influence sulindac sulfide-mediated p21WAF1/CIP1 upregulation in a human prostate epithelial cell line. Oncogene. 2005 Dec 8;24(55):8211-5. [PubMed:16091736]
  4. Kim DJ, Prabhu KS, Gonzalez FJ, Peters JM: Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Carcinogenesis. 2006 May;27(5):1105-12. Epub 2006 Jan 16. [PubMed:16418176]
  5. Liou JY, Ghelani D, Yeh S, Wu KK: Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res. 2007 Apr 1;67(7):3185-91. [PubMed:17409426]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Prostaglandin j receptor activity
Specific Function
Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is al...
Gene Name
PTGDR2
Uniprot ID
Q9Y5Y4
Uniprot Name
Prostaglandin D2 receptor 2
Molecular Weight
43267.15 Da
References
  1. Hata AN, Lybrand TP, Marnett LJ, Breyer RM: Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005 Mar;67(3):640-7. Epub 2004 Nov 24. [PubMed:15563582]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Retinal dehydrogenase activity
Specific Function
Acts as all-trans-retinaldehyde reductase. Can efficiently reduce aliphatic and aromatic aldehydes, and is less active on hexoses (in vitro). May be responsible for detoxification of reactive aldeh...
Gene Name
AKR1B10
Uniprot ID
O60218
Uniprot Name
Aldo-keto reductase family 1 member B10
Molecular Weight
36019.295 Da
References
  1. Cousido-Siah A, Ruiz FX, Crespo I, Porte S, Mitschler A, Pares X, Podjarny A, Farres J: Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10. Chem Biol Interact. 2015 Jun 5;234:290-6. doi: 10.1016/j.cbi.2014.12.018. Epub 2014 Dec 20. [PubMed:25532697]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Russeva VN, Zhivkova ZD: Molecular basis of sulindac competition with specific markers for the major binding sites on human serum albumin. Arzneimittelforschung. 2003;53(3):174-81. [PubMed:12705172]
  2. Shams-Eldeen MA, Vallner JJ, Needham TE: Interaction of sulindac and metabolite with human serum albumin. J Pharm Sci. 1978 Aug;67(8):1077-80. [PubMed:671241]
  3. Zhivkova ZD, Russeva VN: Thermodynamic characterization of the binding process of sulindac to human serum albumin. Arzneimittelforschung. 2003;53(1):53-6. [PubMed:12608015]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13